New direction for Galapagos

Monday 7 November 2022


Galapagos NV is to embark on a new strategic path that will combine its experience in immunology with a bold approach to cell-based therapies for cancer. The strategy was outlined by Paul Stoffels, the chief executive on 4 November, and involves changes to the company’s portfolio and its approach to commercialisation. Dr Stoffels is a former chief scientific officer at Johnson & Johnson Inc who became the Galapagos CEO on 1 April.

The strategy addresses both setbacks and opportunities.